Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
Binghe XuWei LiQingyuan ZhangQiao LiXiaojia WangHuiping LiTao SunYongmei YinHong ZhengJifeng FengHuaqi ZhuAsna SiddiquiHarrison MachariaAdam KnottPublished in: Breast cancer research and treatment (2022)
ClinicalTrials.gov, NCT02896855, registered 7 September 2016.